A Yooper said...
I've been reading this thread and it's original/companion/antithesis thread without jumping in - but I will simply add this: "The Supplement Causing Cancer Story is BS…" - in terms of another position / take on this whole and never-ending discussion. See link at the bottom of this post.
(And once again, my caveat to keep things straight [I really detest having to do this all the time....] is that I am simply providing information I found - this from "Dr. Geo" and from what I garner there are two camps out there, one that hates him and one that loves him; for me, it depends)
So here goes:
drgeo.com/the-supplement-causing-cancer-story-is-bs
Interesting article. He talks about
the "old news" and that is just what I thought when I read the article linked to in the "antithesis thread". I thought I had heard everything in that article quite a long time ago. As well as the reasons some claim these were not good studies, synthetic Alpha E for one example. But regardless, nothing new seemed to me.
However, he put me on to a couple of links. And I have a question. Allen or whoever, I know these are small, but are these RCTs? :
www.ncbi.nlm.nih.gov/pubmed/16263208/Somebody said...
Abstract
Send to:
Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1. Epub 2005 Oct 17.
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH1, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A.
Author information
1Department of Urology, Erasmus MC Rotterdam, The Netherlands. [email protected]
Abstract
OBJECTIVES:
Epidemiological studies have shown significant relationships between the use of dietary components and prostate cancer incidence and mortality. Large studies of primary prevention, which confirm these findings, are desirable but costly and difficult to design. The present tertiary prevention study reports on the effect of a dietary supplement in comparison with placebo on the rate of increase of prostate-specific antigen (PSA).
METHODS:
49 patients with a history of prostate cancer and rising PSA levels after radical prostatectomy (n = 34) or radiotherapy (n = 15) participated in a randomised, double-blind, placebo-controlled crossover study of a dietary supplement. Ethical approval of the protocol was obtained. Treatment periods of 10 weeks were separated by a 4-week washout period. The supplement consisted of soy, isoflavones, lycopene, silymarin and antioxidants as main ingredients. Changes in the rate of increase of PSA (PSA slope and doubling time) were the primary parameters of efficacy. Analyses according to intention to treat (ITT) and per protocol (PP) were carried out.
RESULTS:
Baseline parameters did not differ between randomised groups. Five participants were lost to follow-up, however 46 could be evaluated in an ITT analysis. PP analysis could be performed in 42 men with at least 5 PSA measurements. Per protocol analysis showed a significant decrease in PSA slope (p = 0.030) and (2)log PSA slope (p = 0.041). This translates into a 2.6 fold increase in the PSA doubling time from 445 to 1150 days for the supplement and placebo periods. No treatment-based changes in safety parameters were observed during the study.
CONCLUSIONS:The soy-based dietary supplement utilised in this study was shown to delay PSA progression after potentially curative treatment in a significant fashion. More extensive studies of the supplement may be indicated.
Also:
www.ncbi.nlm.nih.gov/pmc/articles/PMC4020278/Somebody said...
Methods:
In total, 199 men, average age 74 years, with localised prostate cancer, 60% managed with primary active surveillance (AS) or 40% with watchful waiting (WW) following previous interventions, were randomised (2:1) to receive an oral capsule containing a blend of pomegranate, green tea, broccoli and turmeric, or an identical placebo for 6 months..........................
Results:
The median rise in PSA in the food supplement group (FSG) was 14.7% (95% confidence intervals (CIs) 3.4–36.7%), as opposed to 78.5% in the placebo group (PG) (95% CI 48.1–115.5%)..........
Conclusions:
This study found a significant short-term, favourable effect on the percentage rise in PSA in men managed with AS and WW following ingestion of this well-tolerated, specific blend of concentrated foods......................Primary end point
In the FSG, the mean PSA rose from 6.50 to 6.81 ug l−6 from baseline to the end of the intervention, a median PSA percentage rise of 14.7% (95% confidence interval (CI) −3.4% to 36.7%). In the PG, the mean PSA increased from 6.50 to 10.98 ug l−1, a median percentage rise of 78.5% (95% CI 48.1–115.5%). The median percentage PSA increased at a significantly slower rate in the FSG group compared with the PG (difference 63.8% ANCOVA, P=0.0008).
Secondary end point
The number of men with a PSA lower or the same value at trial completion was 61 (46%) in the FSG as opposed to 9 (14%) in the PG. This difference was statistically significant (χ2 value with 1 degree of freedom=19.58, P=0.000010).
Are these RCTs and are the 2 Vit D studies quoted above out of SC RCTs?
Post Edited (BillyBob@388) : 4/25/2015 7:08:56 AM (GMT-6)